key: cord-0926457-f1zofd2f authors: Fernandes, Alan L; Murai, Igor H; Reis, Bruna Z; Sales, Lucas P; Santos, Mayara D; Pinto, Ana J; Goessler, Karla F; Duran, Camila S C; Silva, Carla B R; Franco, André S; Macedo, Marina B; Dalmolin, Henrique H H; Baggio, Janaina; Balbi, Guilherme G M; Antonangelo, Leila; Caparbo, Valeria F; Gualano, Bruno; Pereira, Rosa M R title: Effect of a single high dose of Vitamin D(3) on cytokines, chemokines and growth factor in patients with moderate to severe COVID-19 date: 2022-01-10 journal: Am J Clin Nutr DOI: 10.1093/ajcn/nqab426 sha: 43f5e2174b6e39328b8b98793c27c64ee2ee8ac2 doc_id: 926457 cord_uid: f1zofd2f BACKGROUND: The modulating effect of vitamin D on cytokine levels in severe coronavirus disease 2019 (COVID-19) remains unknown. OBJECTIVES: To investigate the effect of a single high-dose of vitamin D(3) on cytokines, chemokines, and growth factor in hospitalized patients with moderate to severe COVID-19. METHODS: This is a post-hoc, ancillary and exploratory analysis from a multicenter, double-blind, placebo-controlled, randomized clinical trial registered in ClinicalTrials.gov, NCT04449718. Patients with moderate to severe COVID-19 were recruited from two hospitals in Sao Paulo, Brazil. Of 240 randomized patients, 200 were assessed in this study and randomly assigned to receive a single oral dose of 200 000 IU of vitamin D(3) (n = 101) or placebo (n = 99). The primary outcome was hospital length of stay, that has been published in our previous study. The prespecified secondary outcomes were serum levels of interleukin-1β, interleukin-6, interleukin-10, tumor necrosis factor alpha (TNF-α) and 25-hydroxyvitamin D. The post-hoc exploratory secondary outcomes were interleukin-4, interleukin-12p70, interleukin-17A, interferon gamma (IFN-γ), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-8, interferon-inducible protein-10 (IP-10), macrophage inflammatory protein-1 beta (MIP-1β), monocyte chemoattractant protein-1 (MCP-1), growth factor vascular endothelial (VEGF), and leukocytes count. Generalized estimating equations (GEE) for repeated measures, with Bonferroni's adjustment, were used for testing all outcomes. RESULTS: The study included 200 patients with a mean (SD) age 55.5 (14.3) years and body mass index (BMI) 32.2 (7.1) kg/m(2), of which 109 (54.5%) were male. GM-CSF levels showed a significant group by time interaction effect (P = 0.04), although between-group difference at post-intervention after Bonferroni's adjustment was not significant. No significant effects were observed for the other outcomes. CONCLUSIONS: The findings do not support the use of a single dose of 200 000 IU of vitamin D(3), compared to placebo, for the improvement of cytokines, chemokines, and growth factor in hospitalized patients with moderate to severe COVID-19. Clinical Trial Registration: ClinicalTrials.gov, NCT04449718. However, the presumed benefit of vitamin D in improving the cytokine storm remains supported by review (6) (7) (8) (15) (16) (17) and few observational (18) (19) (20) studies. Herein, we report on a post-hoc, ancillary and exploratory analysis from our randomized clinical trial (21) to investigate the effect of a single high dose of vitamin D 3 on systemic inflammatory cytokines, chemokines, and growth factor in hospitalized patients with moderate to severe COVID-19. This is a post-hoc, ancillary and exploratory analysis of secondary outcomes from Eligible patients were assigned in a 1:1 ratio into either the vitamin D 3 group or the placebo group. The randomization list was created using a computer-generated code, in bloc sizes of 20 participants, which was managed by a staff member who had no role in the study. were labeled by a staff member who did not participate in the study, and allocation blindness was kept until the final statistical analysis. Self-reported anthropometric characteristics (weight and height) and coexisting assessed by automated assay. All the assessments described were performed on the day of randomization and on hospital discharge. Importantly, only patients who had blood sample collected on the day of randomization and on hospital discharge were assessed in this study. Therefore, patients who died during follow-up were not included due to the absence of blood samples. The primary outcome, hospital length of stay, was not significantly different between the vitamin D 3 and placebo group as previously published (21) . The prespecified secondary outcomes were serum levels of interleukin-1β, interleukin-6, interleukin-10, TNF-α and 25-hydroxyvitamin D. In order to provide a broader understanding of vitamin D 3 effects on COVID-19related hyperinflammation and immunomodulation, the following exploratory secondary outcomes were included as post-hoc analyses: serum levels of cytokines The intra-assay and inter-assay coefficient of variation (CV) for interleukin-1β (2.3% and 6.7%), interleukin-6 (2.0% and 18.3%), interleukin-10 (1.6% and 16.8%), TNF-α (2.6% and 13.0%), interleukin-4 (2.9% and 14.2%), interleukin-12p70 (2.2% and 16.7%), interleukin-17A (2.2% and 7.9%), IFN-γ (1.6% and 12.0%), and GM-CSF Sample size was chosen based on feasibility and resources, as described in detail in a previous study (21) .Our study was powered considering a repeated measure ANOVA, within-between interaction, at two-sided significance level of 5% ( There were no missing data for cytokines, chemokines, growth factor, and serum 25-hydroxyvitamin D. Missingness for leukocytes count (2 patients in the vitamin D 3 group) was at random and handled by GEE models, with no imputation for missing data. Statistical analyses were performed with IBM-SPSS software, version 20.0. The significance level was set at two-sided P value ≤ 0.05. Of the 1240 patients assessed for eligibility, 240 underwent randomization: 122 patients from the Clinical Hospital of the School of Medicine and 118 patients from the Ibirapuera Field Hospital. Of the 120 patients assigned to the vitamin D 3 group, 1 withdrew the consent, 9 were excluded due to lack of blood sample, and 9 died throughout the follow-up. Of the 120 patients assigned to the placebo group, 2 withdrew consent, 13 were excluded due to lack of blood sample, and 6 died throughout the follow-up (Figure 1 ). Table 2 ). In this post-hoc, ancillary and exploratory analysis from a multicenter, double- Deidentified participant data of this study must be requested from the corresponding author upon publication (sent to rosamariarp@yahoo.com). The codebook of this study will be made available upon request by qualified clinical researchers for specified purposes dependent on the nature of the request and the intention use of the data, with investigator support. The request must include a statistician. The lead author (Dr R M R Pereira) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally 32.2 ± 6.7 32.1 ± 7.5 Body-mass index category, n (%) < 18.5 kg/m 2 0 (0) 1 (1. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1 Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts Vitamin D Receptor polymorphisms and risk of enveloped virus infection: A meta-analysis COVID-19 Disease and Vitamin D: A Mini-Review Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy Active vitamin D supplementation and COVID-19 infections: review Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities Regulation of inflammatory biomarkers by intravenous methylprednisolone in pediatric ARDS patients: Results from a double-blind, placebo-controlled randomized pilot trial Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19 On the use of corticosteroids for 2019-nCoV pneumonia High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution Existing and potentially novel functional markers of vitamin D status: a systematic review Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society Dietary Reference Intakes for Calcium and Vitamin D Evaluation, treatment, and prevention of vitamin D deficiency: an